| DB ID | MyCo_3942 |
| Title | T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study |
| Year | 2018 |
| PMID | 29608751 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | This study was approved by the Ethics Committee of Hospital General Universitario Gregorio Mara~ non (number 2016-024) and the Spanish Agency for Medicines and Health Care Products. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | T2MR+standard cultures |
| Biomarker Full Name | T2Candida MR +standard cultures |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Spain |
| Cohort | This was a prospective observational pilot study conducted in four hospitals located in Madrid, Spain. From January to June 2017, adult hos- pitalized patients who received systemic antifungal therapies for suspected IC were screened daily. 49 patients included. |
| Cohort No. | 49 |
| Age Group | 64.7 + 14.1 |
| P Value | None |
| Sensitivity | 94.2 |
| Specificity | 83.3 |
| Positive Predictive Value | 89.2 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive candidiasis (IC) is the leading cause of fungal disease among hospitalized patients, and is associated with con- siderable morbidity and mortality and a high cost burden. Early treatment in patients with proven candidaemia is associated with reduced mortality and consequently this has produced an increase in early antifungal treatment in patients with risk factors for IC. However, IC is frequently not confirmed until after 3–5 days of empirical treatment, and in this case whether to stop or to continue antifungal agents is a real clinical challenge with influence in antifungal stewardship programmes. |
| Technique | Assay + Immunological assay |
| Analysis Method | Immunofluorescence assay+FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Immunofluorescence assay, FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
